Materia socio-medica · 2025
Reduction of Serum Interleukin-17 and Interleukin-23 Levels Following Narrow Band Ultraviolet B Treatment in Patients with Moderate-to-severe Psoriasis Vulgaris.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phuong Pham Thi Minh, Huyen Tran Thi, Giang Quach Thi Ha, Trang Trinh Minh, Phuong Hoang Thi, Yen Le Thi Hai, Thuong Nguyen Van, Doanh Le Huu
Аннотация
BACKGROUND: Psoriasis, a common skin disorder, involves immune cells and cytokines in its pathogenesis. Narrow band ultraviolet B (NB-UVB) treatment has demonstrated efficacy and safety in managing this condition.
OBJECTIVE: This study aimed to assess changes in serum interleukin (IL)-17, IL-23, and tumor necrosis factor-alpha (TNF-α) levels during NB-UVB treatment for psoriasis vulgaris.
METHODS: An interventional, pre-post comparative study was conducted on patients with moderate to severe psoriasis vulgaris undergoing NB-UVB treatment. Patients were randomly allocated to Group 1 (n=39) receiving NB-UVB based on minimal erythema dose (MED) and Group 2 (n=32) based on Fitzpatrick skin type classification. Serum IL-17, IL-23, and TNF-α levels were measured before treatment and upon achieving PASI75.
RESULTS: There were no significant differences in serum IL-17, IL-23, and TNF-α levels between Group 1 and Group 2 at either time point. In Group 1, IL-17 levels decreased from median 2.6 pg/ml before treatment to 2.5 pg/ml at PASI75 (P=0.0107). In Group 2, IL-23 levels decreased from median 9.6 pg/ml pre-treatment to 1.3 pg/ml at PASI75 (P<0.0190). Across all patients, pre-treatment IL-17 and IL-23 levels (median 2.6 pg/ml and 7.1 pg/ml, respectively) were significantly higher compared to levels at PASI75 (P=0.0349 and P=0.0023, respectively).
CONCLUSION: NB-UVB effectively treats moderate to severe psoriasis vulgaris, leading to reduced serum IL-17 and IL-23 levels irrespective of MED-based or skin type-based dosing strategies.
OBJECTIVE: This study aimed to assess changes in serum interleukin (IL)-17, IL-23, and tumor necrosis factor-alpha (TNF-α) levels during NB-UVB treatment for psoriasis vulgaris.
METHODS: An interventional, pre-post comparative study was conducted on patients with moderate to severe psoriasis vulgaris undergoing NB-UVB treatment. Patients were randomly allocated to Group 1 (n=39) receiving NB-UVB based on minimal erythema dose (MED) and Group 2 (n=32) based on Fitzpatrick skin type classification. Serum IL-17, IL-23, and TNF-α levels were measured before treatment and upon achieving PASI75.
RESULTS: There were no significant differences in serum IL-17, IL-23, and TNF-α levels between Group 1 and Group 2 at either time point. In Group 1, IL-17 levels decreased from median 2.6 pg/ml before treatment to 2.5 pg/ml at PASI75 (P=0.0107). In Group 2, IL-23 levels decreased from median 9.6 pg/ml pre-treatment to 1.3 pg/ml at PASI75 (P<0.0190). Across all patients, pre-treatment IL-17 and IL-23 levels (median 2.6 pg/ml and 7.1 pg/ml, respectively) were significantly higher compared to levels at PASI75 (P=0.0349 and P=0.0023, respectively).
CONCLUSION: NB-UVB effectively treats moderate to severe psoriasis vulgaris, leading to reduced serum IL-17 and IL-23 levels irrespective of MED-based or skin type-based dosing strategies.